NTRK Fusion Gene Positive Advanced Solid Tumor Market Analysis

Type (Diagnosis, Therapeutic)

Diagnosis segment in the NTRK fusion gene positive advanced solid tumor market is expected to hold a share of 54% during the forecast period. Diagnostic testing is being used more widely as a result of rising healthcare professionals' understanding of the value of NTRK fusion gene testing in determining which patients are eligible for targeted therapy. NTRK fusions can be identified using a variety of techniques, including pan-TRK immunohistochemistry, fluorescence in situ hybridization, and sequencing approaches. In particular, for tumor histologies with a high prevalence of NTRK fusions involving recurrent partners (MASC, infantile fibrosarcomas, secretory breast carcinoma, and cellular or mixed congenital mesoblastic nephromas), FISH and RT-PCR are reasonable alternatives to NGS in the detection of NTRK fusions. These techniques have been successfully used in the clinic. The segment share is increasing in part due to recent approvals.

End-Users (Hospitals, Specialty Clinics, Cancer Centres, Cancer Research Institutes)

Hospitals segment for the NTRK fusion gene positive advanced solid tumor market is expected to hold a share of 43% during the projected period. The healthcare industry, and notably hospitals, is the most lucrative end-user for the NTRK fusion gene-positive advanced solid tumors market. Healthcare facilities are leading the way in the application of NTRK fusion gene-positive advanced solid tumor treatments due to the high incidence of advanced solid tumors and the increasing emphasis on precision medicine. NTRK fusion gene-positive tumors are those that have been identified in a patient with mutant NTRK genes. It is unclear how frequently NTRK fusions occur, even though they are uncommon and represent approximately 1% of solid tumors. The accurate technique for identifying NTRK fusion genes is DNA Next Generation Sequencing (NSG) technology.

Our in-depth analysis of the global NTRK fusion gene positive advanced solid tumor market includes the following segments: